Anti-PSMA 124I-scFvD2B as a new immuno-PET tool for prostate cancer: preclinical proof of principle.
Frigerio B, Morlino S, Luison E, Seregni E, Lorenzoni A, Satta A, Valdagni R, Bogni A, Chiesa C, Mira M, Canevari S, Alessi A, Figini M.
Frigerio B, et al. Among authors: chiesa c.
J Exp Clin Cancer Res. 2019 Jul 23;38(1):326. doi: 10.1186/s13046-019-1325-6.
J Exp Clin Cancer Res. 2019.
PMID: 31337429
Free PMC article.